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Calliandra portoricensis is a medicinal plant growing freely in Nigeria. It is
used traditionally to treat tuberculosis, as an anthelmintic and an abortifacient.
Phytochemical fractionation and screening of its root extracts has yielded
a novel (5-hydroxy-7-methoxy-4-oxo-1-chromanyl)-4-methoxy-p-benzoquinone
(breverin)-substituted cassane diterpene, which was designated bokkosin. It was
obtained from column chromatography of the ethyl acetate extract of the roots.
The compound was characterized using IR, NMR (1D and 2D) and mass spectral
data. Promising antiparasitic activity was observed against the kinetoplastid parasite
Trypanosoma brucei brucei, as well as moderate activity against Trypanosoma
congolense and Leishmania mexicana and low toxicity in mammalian cells, with the
best in vitro EC50 values against T. b. brucei (0.69µg/mL against a standard laboratory
strain, and its multi-drug resistant clone (0.33µg/mL). The effect on T. b. brucei in
culture was rapid and dose-dependent, leading to apparently irreversible growth arrest
and cell death after an exposure of just 2 h at 2 × or 4 × EC50. The identification of
bokkosin constitutes the first isolation of this class of compound from any natural source
and establishes the compound as a potential trypanocide that, considering its novelty,
should now be tested for activity against other microorganisms as well.
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INTRODUCTION
Calliandra portoricensis Benth (Fabaceae) is a shrub or small tree that can grow to about six meters
tall. C. portoricensis is one of the plants used by Nigerian traditional medical practitioners to treat
various infections including tuberculosis. It is used as a laxative/worm expeller (Falode et al., 2018)
and an abortifacient in humans (Ayensu, 1978). The plant is distinctly ornamental, with white
hemispherical flower heads and fern-like foliage. In Ghana, the root is mixed with ginger and
pepper for use as an enema for lumbago pain and constipation, and to treat gonorrhea. The plant
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has also been reported for its anticonvulsant, analgesic,
antidiarrheal, antispasmodic, antipyretic, anti-snake venom, and
antirheumatic properties (Adesina, 1982; Akah and Nwaiwu,
1988; Agunu et al., 2005). In addition, it has exhibited
anticholinergic, antacid, antiulcer, molluscicidal, and ovicidal
activities in laboratory animals (Aguwal and Lawal, 1988),
as well as activity on cancer cells (Ogbole et al., 2017;
Oyebode et al., 2019). The plant extracts have been reported to
possess antimicrobial activity against the following pathogens:
Escherichia coli, Staphylococcus aureus, Streptococcus faecuim
and Candida albicans, Enterococcus faecalis, and Streptococcus
pneumonia (Adesina, 1982; Agunu et al., 2005; Enwuru et al.,
2017). A pre-purified peptide fraction from C. portoricensis
also showed promising anti-bacterial efficacy, including to
methicillin-resistant S. aureus (Ogbole et al., 2020). However,
although the plant clearly has medicinal properties, it has not yet
been investigated for antiparasitic activity, and active agents have
yet to be identified from the extracts.
Kinetoplastid protozoan parasites cause some of the
world’s most neglected infectious diseases, trypanosomiasis,
and leishmaniasis. Different species of Trypanosoma are
responsible for debilitating diseases of humans (Human
African trypanosomiasis, HAT) and animals (Animal African
trypanosomiasis, AAT), transmitted by the tsetse fly, mainly
in tropical Africa, as well as Chagas disease, which affects
large numbers of people in South and Central America and is
transmitted by reduviid bugs (Barrett et al., 2003; Pérez-Molina
and Molina, 2018). Tsetse-borne trypanosomiases are endemic
in 37 out of 54 African countries, with serious economic and
public health consequences (Yaro et al., 2016; Büscher et al.,
2017). Although significant progress is being made toward
the elimination of HAT as a major public health problem in
Western Africa (Franco et al., 2018; Akazue et al., 2019), tens
of millions of cattle, sheep, and goats as well as millions of
donkeys, camels and horses are at risk of AAT (Giordani et al.,
2016) including in Central and Northern Nigeria (de Gier et al.,
2020). Leishmaniasis, on the other hand, is caused by at least
20 species of the genus Leishmania, and is endemic in about
100 countries, mostly in the tropics and subtropics, with an
estimated 0.7–1 million cases annually; the disease is transmitted
by phlebotomine sandflies and consists of cutaneous, mucosal
and visceral clinical forms depending on the species (Burza et al.,
2018).
Chemotherapy for both trypanosomiasis and leishmaniasis is
based on old drugs and is associated with a myriad of challenges
such as drug toxicity, chemoresistance, and a lack of guaranteed
supply (Delespaux and De Koning, 2007; Burza et al., 2018;
Altamura et al., 2020; de Koning, 2020). Therefore, there is an
urgent need for new treatment approaches. Nevertheless, the
progress in discovering new and effective antiparasitic drugs
has been very poor. Possible reasons for this include an over
confidence in the validation of single molecular targets such
as enzymes or receptors and a lack of fundamental knowledge
on the biology and metabolism of these kinetoplastids (Field
et al., 2017). An alternative approach to high throughput
screening against a single target protein, which may accelerate
the discovery of novel leads, is to use high throughput phenotypic
screening assays against live parasites in vitro (Nagle et al., 2014;
Peña et al., 2015). Such phenotypic screening may be more
time effective in lead generation, as it has the advantage of
identifying compounds that are able to cross cell membranes and
additionally, identify active compounds with unknown and/or
multiple targets. Such compounds might not be identified in a
screen with a defined single target such as an enzyme (Field
et al., 2017), sometimes because they accumulate strongly in a
particular cellular compartment (Lüscher et al., 2007), e.g. the
mitochondrion (Alkhaldi et al., 2016; Fueyo González et al.,
2017).
Nature has been a rich source of biologically active
compounds for the development of new pharmacological agents
themselves or from which active compounds have been derived
using their novel structures as a template, over the past decades
(Cragg and Newman, 2005; Newman and Cragg, 2020). Several
compounds isolated from natural sources have been shown to
inhibit the growth of trypanosomes in vitro and in vivo, e.g.,
cordycepin and its chemical analogs (Vodnala et al., 2013; Hulpia
et al., 2018, 2019a), isolated from the fungus Cordyceps militaris,
and quercetin and its derivatives, which is a polyphenolic
flavonoid commonly found in plants (Mamani-Matsuda et al.,
2004). Other examples include the trypanocidal activity of
two dipeptide compounds isolated from the roots of Zapoteca
portoricensis (Nwodo et al., 2014), a clerodane-type diterpenoid
isolated from Polyalthia longifolia (Ebiloma et al., 2018a), steroid
alkaloids from Holarrhena africana (Nnadi et al., 2019) and the
anti-kinetoplastid properties of propolis (Alotaibi et al., 2019;
Siheri et al., 2019).
In this study, we report the isolation of a novel breverin-
substituted cassane diterpene, designated bokkosin, from the
Nigerian indigenous medicinal plant C. portoricensis, and
examined its in vitro activity against kinetoplastid parasites and
its toxicity to mammalian cell lines.
MATERIALS AND METHODS
Chemical Extraction and Characterization
Plant Material
The roots of C. portoricensis were purchased from a traditional
healer in Jos market, Plateau State, Nigeria, certified at the
Department of Forestry Technology, Federal School of Forestry,
Jos, Nigeria, and a voucher specimen with herbarium number
NIPRD/H/6244 was deposited at the National Institute for
Pharmaceutical Research and Development (NIPRD) Abuja,
Nigeria. The roots were dried at room temperature for 2 weeks,
before being ground into a powder and used for extraction.
Equipment
The IR spectrum was acquired on a Shimadzu IRAffinity-1
spectrophotometer while the 1H and 13C NMR spectra were
run on a Bruker AVIII (400 MHz) spectrophotometer (1H, 100
MHz; 13C, 400 MHz) using deuterated benzene C6D6 as the
solvent. The LC-HRMS was run on a Bruker Compass LC-
MS spectrometer. Column chromatographic separations were
carried out in glass columns using silica gel (200–400 mesh)
and spots on thin layer chromatography [TLC grade Silica
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gel 60 F253, Merck KGaA (Darmstadt, 64293, Germany)] were
visualized using ethanol:sulfuric acid (90:10) reagent. Solvents
for extraction and column chromatography were purchased from
Sigma Aldrich, United Kingdom.
Extraction
The powdered root (1.50) kg was successively extracted using
cold maceration with 3 liters of hexane and ethyl acetate (HPLC
grade, Sigma Aldrich, United Kingdom) for 72 h each. The
extracts were concentrated on a rotatory evaporator at 40◦C
under vacuum and subsequently evaporated to dryness on a
water bath to obtain 18.7 g of hexane (12.5%) and 34.5 g of ethyl
acetate (23.0%) extracts. The ethyl acetate extract (1.20 g) was
dissolved in ethyl acetate and adsorbed on silica gel (200–400
mesh, 10 g, Merck Germany,). The slurry was allowed to dry
at room temperature and a dark-brown powder was obtained.
A glass column (diameter 6 × 50 cm height) was wet-packed
with silica gel (200–400 mesh, 100 g) using hexane as the solvent.
The adsorbed extract was loaded onto the column and eluted
with 300mL each of increasing ratios of ethyl acetate in hexane:
100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90,
0:100, with collection of 20mL fractions. The fractions were
monitored by TLC on pre-coated aluminum sheets coated with
silica gel F250 (Merck, Germany) and on that basis grouped
into eight combined fractions (F1 to F8). Fraction F3 (30%
ethyl acetate) was subjected to further column chromatography.
Another column was similarly packed with 50 g of silica gel
and eluted using increasing amounts of ethyl acetate in hexane,
resulting in the isolation of compound 1.
Determination of Biological Activity
Parasites, Mammalian Cell Lines, and Culture
The kinetoplastid parasites used in this study included the
bloodstream form (BSF) of T. b. brucei s427WT and the
derived drug resistant clone B48 that lacks both the TbAT1/P2
transporter and the high affinity pentamidine transporter
(HAPT1) and is therefore highly resistant to diamidine and
melaminophenyl arsenical drugs (Bridges et al., 2007). For T.
congolense BSF IL3000WT and its 6C3 diminazene resistant
clone, generated through in vitro drug exposure, were used
(Alotaibi et al., 2019). As a sample Leishmania species, L.
mexicana cas9/T7 (Beneke et al., 2017) and the derived L.
mexicana cas91NT1 promastigotes were used. The T. b. brucei
strains were cultured at 37◦C in a 5% CO2 atmosphere, in
HMI-9 medium (Invitrogen, UK) supplemented with 10%
(v/v) heat inactivated fetal bovine serum (FBS), 14 µL/L β-
mercaptoethanol, and 3.0 g/L NaHCO3 adjusted to pH 7.4 as
described previously (de Koning et al., 2000). T. congolense
strains were cultured at 34◦C/5% CO2, essentially as described
previously (Coustou et al., 2010; Ebiloma et al., 2018b) in basal
medium prepared with MEM medium (Sigma-Aldrich), 26mM
NaHCO3, 25mM HEPES, 5.6mM D-glucose, 1mM sodium
pyruvate, 100µM hypoxanthine, 40µM adenosine, 16.5µM
thymidine, and 25µM bathocuproine disulfonic acid disodium
salt, and supplemented with 1.6mM glutamine, 100 units/mL
penicillin, 0.1 mg/mL streptomycin, β-mercaptoethanol
(0.0014%, v/v), 15% (v/v) goat serum (Gibco, United Kingdom),
and 5% (v/v) Serum Plus II (Sigma-Aldrich, United Kingdom).
L. mexicana strains were cultured at 25 ◦C and 5% CO2 in
HOMEM medium supplemented with 10% (v/v) FBS and 1%
(v/v) penicillin/streptomycin solution (Gibco, United Kingdom)
(Al-Salabi et al., 2003; Khandazhinskaya et al., 2019). Human
U937 cells (European Collection of Cell Cultures Cat. No.
85011440, supplied by Sigma-Aldrich, United Kingdom), were
cultured in RPMI 1640 medium (Lonza, United Kingdom)
supplemented with 5% (v/v) FBS, 1% (v/v) L-glutamine and 1%
(v/v) penicillin/streptomycin at 37◦C in a humidified atmosphere
of 5% CO2 as previously described (Passmore et al., 2001). RAW
264.7 (ATCC TIB-71, United States) murine macrophages were
cultured using ATCC-formulated Dulbecco’s Modified Eagle’s
Medium (DMEM) (Catalog No. 30-2002) supplemented with
10% (v/v) FBS, 1% (v/v) glutamine, and 1% (v/v) penicillin-
streptomycin at 37◦C in a humidified atmosphere of 5% CO2
(Han et al., 2002).
Construction of the Derived L. Mexicana cas91NT1
Cell Line
The closely related genes LmexNT1.1 and LmexNT1.2 transport
adenosine, thymidine, and uridine (Alzahrani et al., 2017;
Campagnaro and De Koning, 2020) as well as a number of purine
and pyrimidine nucleoside analogs with strong antileishmanial
activity, including the antibiotic tubercidin (Vasudevan et al.,
1998; Aoki et al., 2009), and 5-F-2′-deoxyuridine (Alzahrani
et al., 2017). Since these genes are functionally highly conserved
in Leishmania species (Alzahrani et al., 2017) and tubercidin
analogs have recently been reported to have excellent anti-
kinetoplastid activity in vitro and in vivo (Hulpia et al., 2018,
2019a,b; Lin et al., 2019) this strain was included here as a further
control. The knockout strategy for the NT1.1/NT1.2 allele in L.
mexicana cas9 was performed as described previously (Beneke
et al., 2017). Briefly, primers 1 to 5 (Supplementary Table 1)
were used to produce NT1 KO in L. mexicana cas9 and these
primers were designed using the LeishGEdit online platform
(Beneke et al., 2017). The deletion of the NT1 locus requires the
amplification of two sgRNAs, using primers 1–3 to direct Cas9 to
cut immediately upstream (5′) or downstream (3′) of the target
locus of NT1. To create CRISPR plasmids specific to the target
locus ofNT1, pTBlast, and pTPuro plasmids (with blasticidin and
puromycin cassettes, respectively), were amplified using primers
4 and 5. These constructs were to integrate into the NT1 locus
after cutting with the two sgRNAs. Thus, to yield the NT1 KO, L.
mexicana-cas9 was transfected once, with two sgRNA templates
and two antibiotic resistance markers (pTBlast and pTPuro). The
combination of the two antibiotic resistance markers was used to
create homozygous cells that do not retain a copy of NT1. The
loss of the NT1 locus in drug-resistant transfectants was verified
by performing PCR diagnostics to amplify PCR products within
the open reading frame of the NT1 locus, using primers that are
unique to the NT1 locus. A region of the NT1 amplicon was
amplified with genomic DNA-specific primers (forward primer,
5′- TCCGCTGCAAACAAACTTCTGG-3′; reverse primer, 5′-
TACGCCGCTACGATGATCCAGC-3′) and PCR products were
run on 1% agarose gel to be observed visually. PCR diagnostics
of the L. mexicana cas9 and L. mexicana cas91NT1 cell lines
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TABLE 1 | Seeding density, culture conditions, and incubation period for resazurin-based assays in different parasite cell lines.
Cell line Seeding density Condition Incubation time (h)
(cells/well) Initial + resazurin
T. b. brucei 427WT and B48 2 × 104 37◦C, 5% CO2 48 24
T. congolense Tc-IL3000 WT and T.
congolense 6C3
5 × 104 34◦C, 5% CO2 48 24
L. mexicana cas9/T7 and cas91NT1 4 × 105 27◦C 72 48
showed the expected presence and absence ofNT1-specific bands
in the parental cell line and the KO clone, respectively (∼1 kb)
(Supplementary Figure 1).
Determination of the Cytotoxic Effect of Bokkosin on
U937 and RAW 246.7 Mammalian Cell Lines
The cytotoxic effect of bokkosin on RAW246.7 was carried out
as previously described (Han et al., 2002; Ayupova et al., 2019).
Cells were grown to log phase and adjusted to a density of 1 ×
105 cells/ml. One hundred microlitre/well of the cells were added
to a 96 well plate (TPP, Switzerland) and the plate incubated for
24 h at 37◦C, 5% CO2, 100% humidity. The stock solution was
prepared in another 96 well plate in 8 different concentrations
in the full, supplemented DMEM medium (section Parasites,
mammalian cell lines, and culture) using 1:1 serial dilution
(i.e., starting from 200µg/mL as the top concentration until
1.56µg/mL). The samples were then transferred (100 µL) to
the cultured cells using a multichannel pipette and left in the
incubator for 24 h. After incubation, 5mM resazurin sodium
salt (Sigma Aldrich, UK) was added (20 µL per well) and the
plate incubated for a further 24 h. Fluorescence readings of the
plate were taken using a Perkin Elmer Wallac Victor2 microplate
reader (λex/em: 544 and 590 nm). While, U937 cells were grown
to log phase, counted and adjusted to a density of 1 × 105
cells/mL. A volume of 100 µL of cells was then added to each
well of a 96-well plate (TPP, Switzerland) and incubated for 24 h
at 37 ◦C, 5% CO2 and 100% humidity. From a 200µg/mL stock
solution, a 2-fold serial dilution of the test compound was carried
out in the full, supplemented RPMI medium, (section Parasites,
mammalian cell lines, and culture) to determine the EC50 value
for the samples. In another 96-well plate, 100 µL of each dilution
was transferred to the cultured cells using a multichannel pipette,
followed by incubation for 24 h. Controls consisted of: 10%
(v/v) DMSO (positive, cell death control), cells and medium
(negative control) and 0.5% (v/v) DMSO (solvent control). This
was followed by addition of 20 µL of 5mM resazurin sodium
salt (Sigma Aldrich, United kingdom) and the plates incubated
for a further 24 h after which fluorescence was measured using
a Wallac Victor 2 (Perkin Elmer, United Kingdom) microplate
reader (λexc = 560 nM, λem = 590 nm). The compound was
tested in triplicate and cell viability was expressed as a percentage
of the drug-free control. The resulting data were analyzed
using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego)
to obtain a dose-response curve and the mean 50% effective
concentration (EC50) value.
Determination of in vitro Anti-trypanosomal and
Anti-leishmanial Activity of Bokkosin
Bokkosin was tested against BSF T. b. brucei s427 WT and
T. b. brucei B48; BSF T. congolense Tc-IL3000 WT and T.
congolense 6C3; and L. mexicana cas9/T7 and L. mexicana
cas91NT1 promastigotes in order to assess its antiparasitic activity
and the potential for cross-resistance with existing drugs using
resazurin-based assays as described previously (Fueyo González
et al., 2017; Eze et al., 2019; Khandazhinskaya et al., 2019). This
assay is based on the fact that the blue non-fluorescent dye
resazurin is metabolized by live, but not dead cells, including
Trypanosoma and Leishmania species, to the red, fluorescent
compound resorufin (Gould et al., 2008). Briefly, 11 double
dilutions of the compound (in the appropriate culture medium
for the species) were prepared from 20 mg/mL stock solution in
96-well plates (Greiner Bio-one GmbH, Germany), starting from
200µg/mL down to 0.19µg/mL with the 12th well containing
no drug. Dilutions of pentamidine or diminazene were prepared
in parallel to serve as positive controls. The cells were then
adjusted to twice the required density in the appropriate medium
and added to the wells containing drug dilutions followed by
incubation for 48 or 72 h, as shown in Table 1, after which
20 µL of 125µg/mL resazurin sodium salt (Sigma Aldrich,
United Kingdom) in phosphate-buffered saline (PBS, Sigma
Aldrich, UK) was added. The plates were further incubated
for 24 or 48 h under the same conditions and fluorescence
was determined using a FLUOstar Optima plate reader (BMG
Labtech, United States), λexc = 544 nM, λem = 590 nm. The
results were expressed as half maximal effective concentration
(EC50) values, which were calculated by non-linear regression
using an equation for a sigmoidal dose-response curve with
variable slope (GraphPad Prism 5.0).
Effect of Bokkosin on the Growth of T. b. brucei s427
Wild Type
The effect of different concentrations of bokkosin, on the growth
of T. b. brucei s427 wild type in vitro was tested following
continuous exposure over 48 h, as described previously (Hulpia
et al., 2019a). Briefly, the cells were counted and adjusted to a
density of 2 × 105 cells/mL in 5mL of either fresh complete
HMI-9 medium or in medium containing bokkosin at 0.5×,
1×, 2×, and 4× EC50 (determined by the resazurin-based assay,
above) in 25-mL culture flasks. The flasks were incubated at 37◦C
and 5% CO2 and the cells of each culture were counted in a
Neubauer counting chamber under a phase-contrast microscope
in triplicate at several time points (0, 2, 6, 12, 18, 24, 30, 36,
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42, and 48 h) for each concentration of the compound, as well
as the no drug control. An additional experiment, using a wash-
out of the test compound at just 2 h was performed to investigate
whether limited exposure time would be sufficient for irreversible
impact on cell growth. In this case, cells were washed after the
2-h drug incubation, by centrifugation at 1,600 ×g, followed by
reconstitution in the same volume of fresh media. The growth
experiments were performed on three separate occasions and the
mean used to plot the growth curve.
RESULTS AND DISCUSSION
Characterization of Compound 1
(Bokkosin) as a
(5-hydroxy-7-methoxy-4-oxo-1-
chromanyl)-4-methoxy-p-benzoquinone
(breverin)-Substituted Cassane Diterpene
Compound 1 (80.0mg) was obtained as a white
crystalline solid (mp 290–301◦C). The LC-MS spectrum
(Supplementary Material 1) gave a [M+H]+ ion at m/z
= 633.4234 (calcd 633.3064, C37H45O9) corresponding to
the molecular formula C37H44O9, and having 16 units of
unsaturation. The IR spectrum (Supplementary Material 2)
showed absorption frequencies for ketone carbonyls (C=O)
between 1,700 and 1,750 cm−1, C-H at 2,900, C-O at 1,200 and
1,250, aromatic and alkene C=C double bonds in the region
of 1,450–1,600 and aromatic substitution between 800 and
900 cm−1. The proton spectrum (Supplementary Material 3)
showed a deshielded proton signal for a hydrogen bonded
hydroxyl group at δH 12.30 typical of a 5-hydroxy flavanone
moiety. There were signals corresponding to six methyl groups
made up of three aliphatic singlets at δH 0.69, 0.74, 0.79 (3H, s),
one doublet at 1.00 (3H, d, J = 7.1Hz) and two highly shielded
methoxy groups at 2.82 and 3.03 (3H, s). It also showed eleven
methine signals made up of seven aliphatic methine protons at
δ 0.63, 1.34, 1.35, 2.01, 3.48, 3.58, 3.66, two aromatic methine
protons at 6.02 and 6.11, and two olefinic protons at 5.09 and 5.62
ppm. The spectrum also had signals for seven pairs of methylene
protons. The 13C NMR spectrum (Supplementary Material 4)
showed signals for 37 carbon atoms consisting of three ketone
carbonyls at δC 192.3, 193.3, 194.1, five quaternary aromatic
carbons at 102.5, 158.8, 164.0 (–OH substituted), 161.1 and 167.7
(-OCH3 substituted), 141.2 for an olefinic quaternary, and 110.6
for a quaternary acetal carbon. There were signals for six methyl
carbons at δC 11.4, 14.6, 21.3, 33.6,54.7, 55.3, the latter two being
methoxys, three oxymethines at δC 54.7, 55.3, 82.5 ppm and
seven methylene carbons at 18.8, 21.6, 29.2, 31.2, 40.4, 41.7, and
45.8 ppm. It also showed eleven methine carbons consisting of
two aromatic ones at 94.4 and 95.4, two olefinic methines at
111.1 and 113.1 and six aliphatic ones at 39.6, 41.6, 44.4, 45.4,
52.7, 54.2 ppm. Using the 2D NMR (COZY, HSQC, HMBC,
Supplementary Materials 5–7) spectra for the compound, the
structure (Figure 1) was established as follows: the two aromatic
protons at δ 6.02 (d, J = 2.4Hz) and 6.11 (d, J = 2.4Hz) were
meta coupled and confirmed the substitution in ring A of the
flavanone part with strong HMBC correlations to one another’s
carbons and to C-7′ and C-10′. Long range correlations from
the chelated –OH proton at 12.30 ppm to C-5′, C-6′, and
C-10′ confirmed the –OH to be at C-5′ and the carbonyl at
C-4′. The chemical shift of the C-4′ carbonyl was at 193.3 ppm
indicating a saturated ring ketone, confirmed by methylene
proton (H-3′) correlations to it and to C-2′ (a quartenary carbon
with chemical shift (δ 110.6) similar to that of a di-oxygenated
acetal-type carbon). One of the H-3′ protons (δH 2.88) also
correlated with C-10′. The methylene protons both correlated
with another quaternary carbon (δ 62.3) which was not part of
the chromanone ring system and must be C-1′′. This carbon also
had correlations from protons at δH 5.62 and 3.66 and both of
these protons, H-3′′ and H-6′′, respectively, correlated with two
carbonyls (C-2′′ & C-5′′) and a methoxy-bearing carbon (C-4′′,
δC 161.4) completing a six-membered quinonoid ring-B of the
flavonoid part of the molecule. This accounts for 17 carbons
in total for the flavanone portion of the molecule bearing two
methoxy groups. There are now 20 carbons in the rest of the
molecule including four methyl groups and one double bond and
the proton spectrum (Supplementary Material 2) was typical
of a diterpene-type moiety. This was confirmed in the HMBC
(Supplementary Material 7) by long range correlations from two
geminal methyl groups H-18 and H-19, identifying C-3, C-4, C-
5, and their carbons C-18 and C-19. Further, correlations from
the H-17 doublet to C-13 indicated a double bond between C-13
and C-15. Correlations from H-15 to C-12 and C-16 and from
H-20 to C-1, C-5, C-9 and C-10 confirmed the diterpene to be a
cassane type skeleton. The cassanemoietymust be attached to the
flavanoid B-ring via the connections C-12 to C-1′′ and C-16 to C-
6′′ as there were COZY (Supplementary Material 5) correlations
between H-16 and H-6′′ and HMBC (S7) correlations between
H-12 and the quinonoid carbonyl (δC 194.1) C-2
′′ and H-16 with
C-1′′ and C-5′′. There was even a significant long range zig-zag
4J correlation in the HMBC spectrum between H-3′′ and C-12.
Taking all of the atoms from both flavonoid and diterpenoid
moieties into account, there remained two oxygens unaccounted
for in the above arguments. These must be attached as a peroxide
bridge between C-11 and C-2′ and the chemical shifts of these
two carbons (82.5 and 110.6 ppm, respectively) testify to this
proposition. The NOESY spectrum (Supplementary Material 8)
revealed the strong correlations between the methoxys and their
ortho-proton neighbors, established the relative stereochemistry
within the cassane moiety and between cassane H-12 (δH 3.48)
and the flavanoneH-3′ (δH 2.88) (Figure 1). Thus, the compound
was characterized as a novel 2-(5-hydroxy-7-methoxy-4-oxo-2-
chromanyl)-5-methoxy-p-benzoquinone (breverin) (Allan et al.,
1973) substituted at C-12 and C-16 of a cassane diterpene with
a peroxide bridge between C-11 of the diterpene and C-2 of the
breverin part (Figure 1) and named bokkosin. The 1H and 13C
chemical shift assignments in C6D6 are given in Table 2.
In vitro Antitrypanosomal and
Antileishmanial Activity and Cross
Resistance Studies of Bokkosin
The in vitro activity of bokkosin on wild-type T. b. brucei
s427 and the derived, multi-drug resistant clone B48
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FIGURE 1 | Structure of bokkosin and its 2D correlations. (A) COZY (Dark lines), NOESY (Arrows), (B) HMBC (Arrows).
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(Munday et al., 2014) was determined in three independent
resazurin-based drug sensitivity assays as shown in Table 3.
Bokkosin displayed potent activity against T. b. brucei s427
with an EC50 value of 0.69 ± 0.04µg/mL, corresponding to
approximately 1µM, and was not cross resistant to pentamidine.
In fact, the B48 clone was significantly more sensitive to
bokkosin (P = 0.0017; Student’s unpaired, two tailed t-test)
with a Resistance Factor (RF) of 0.49 compared to 159-fold
resistance for pentamidine (P < 0.0001). Given the highly
promising activity observed against T. b. brucei s427 and T. b.
brucei B48, it was decided to determine the activity of compound
1 against T. congolense, which is the most important etiological
agent of AAT (Giordani et al., 2016). Although not as active as
against T. b. brucei, bokkosin showed modest activity against
T. congolense IL3000 WT (Table 4) but the EC50 of 21.6µM
does not justify further development against this parasite. No
cross-resistance to the widely used drug diminazene aceturate
was observed (RF relative to T. congolense 6C3 was 0.81; P>0.05)
as shown in Table 4. Interestingly, bokkosin was somewhat
more active against the diamidine-resistant strains of T. b.
brucei and T. congolense than against the sensitive controls,
although this was only statistically significant for brucei. It is
difficult to speculate at this point as to the reasons for this.
However, it is known that the diamidine transporters of both
trypanosome species are completely different, and thus those
drug transporters are highly unlikely to be involved in the
uptake of bokkosin; however, in both species these cationic
diamidines target the mitochondrion aided by the mitochondrial
membrane potential, which is reduced in T. congolense 6C3
(Carruthers et al., 2020). A possible interpretation of these
observations would be that the target for bokkosin is not
mitochondrial. However, this is a new compound and as such the
mechanism of its trypanocidal action is a matter of speculation
at this moment.
Bokkosin was also tested against two cell lines of L. mexicana,
a species that causes severe cutaneous leishmaniasis from the
southern United States to the northern regions of South America
(Kevric et al., 2015). CRISPR technology was used and the L.
mexicana cas9/T7 strain (Beneke et al., 2017) to knockout both
copies of the NT1.1 - NT1.2 allele from the genome. As expected,
the cas91NT1 strain was highly resistant to tubercidin (56.6-
fold; P < 0.0001). Bokkosin displayed low micromolar activity
against promastigotes of the cas9/T7 strain and no significantly
difference against cas91NT1 (P > 0.05), as shown in Table 5.
This preliminary result against the promastigote (insect) form
was not deemed to be sufficiently encouraging to continue to test
against intra-macrophage amastigotes, which would be necessary
for a more definitive indication of clinical potential, particularly
since the activity against multidrug resistant T. b. brucei was
ten-fold higher.
Effect of Bokkosin on in vitro Growth of
T. brucei s427 WT BSF
In order to verify whether bokkosin is trypanocidal or
trypanostatic, its effect was tested on log phase growth of T.
brucei 427WT BSF culture over time. The growth curves of the
TABLE 2 | 1H and 13C chemical shifts of compound 1 in C6D6.
Position Chemical shift HMBC
1H [δ ppm, mult, J (Hz)] 13C (δ ppm, mult)
1 0.92 (m), 1.84 (dq, 13.6, 2.8) 40.4 (CH2) C-3,C-5,C-20
2 1.15, 1.25(m) 18.5 (CH2) C-4, C-10
3 1.03, 1.18 (m) 41.7 (CH2) C-7, C-19, C-20
4 – 32.9 (C)
5 0.63 (dd, 2.0, 2.2) 54.2 (CH) C-7, C-19, C-20
6 1.45 (m), 1.02 (m) 21.6 (CH2) C-8, C-10
7 1.13 (m), 1.32 (m) 31.2 (CH2) C-5,C-14
8 1.35 (m) 39.6 (CH) C-11,C-13, C-17
9 1.34 (m) 52.7 (CH) C-10, C-14
10 37.7 (C)
11 3.57 (m) 82.5 (CH) C-9, C-12, C-1′′
12 3.48 (d, 11.3) 44.4 (CH) C-9, C11, C-2′′
13 141.2 (C)
14 2.01(m) 41.6 (CH)
15 5.10 (dt, 6.4, 1.8) 113.1 (CH) C-12, C-16
16 2.12 (dt, 16.7, 5.6), 2.00 (m) 29.2 (CH2)
17 1.00 (d, 7.1) 14.6 (CH3) C-8, C-13, C-14
18 0.79 (s) 33.6 CH3) C-3, C-4, C-5, C-19
19 0.69 (s) 21.3 CH3) C-3, C-4, C-5, C-18
20 0.74 11.4 CH3) C-1, C-5, C-9, C-10
1′
2′ 110.6 (C)
3′ 2.90, 2.88 (ABq,16.1) 45.8 (CH2) C-2
′, C-10′, C-1′′
4′ 193.3 (C)
5′ 164.0 (C)
6′ 6.02 (d, 2.4) 94.4 (CH) C-7′, C-8′, C-10′
7′ 167.7 (C)
8′ 6.11 (d, 2.3) 95.4 (CH) C-6′, C-7′, C-10′
9′ 158.8 (C)
10′ 102.5 (C)
1′′ 62.3 (C)
2′′ 194.1 (C)
3′′ 5.62 (s) 111.1 (CH) C-2′′, C-3′′, C-4′′
4′′ 161.4 (C)
5′′ 192.3 (C)
6′′ 3.66 (dd, 12.2, 5.0) 45.4 (CH) C-16, C-2′, C-1′′,C-2′′,
C-4′′, C-5′′
5′-OH 12.30 (s) C-5′, C-6′, C-10′
7′-OCH3 3.03 (s) 54.7 (CH3) C-7
′
4′′-OCH3 2.85 (s) 55.3 (CH3) C-4
′′
parasite following a 2 h short exposure and continuous exposure
to bokkosin are shown in Figures 2A,B.
The result shows that continuous exposure to bokkosin for
48 h achieves complete clearance of trypanosomes from the
culture, even at half the EC50 concentration; no live cells were
detected after exposure times of 36, 24 and 18 h, respectively
for 1×, 2×, and 4× EC50 concentration, respectively. Following
only a short exposure of 2 h, the effect appears to be a prolonged
growth arrest, as cultures incubated with it at 0.5×, 1×, and 2×
EC50 were still able to grow, albeit at a very slow rate dependent
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TABLE 3 | EC50 of bokkosin on T. b. brucei S427 WT and T. brucei B48.
Sample T. brucei s427 WT T. brucei B48 (Pentamidine Resistant)
EC50 EC50 RF t-test
(µg/mL) (µM) (µg/mL) (µM)
Bokkosin 0.69 ± 0.04 1.09 ± 0.06 0.33 ± 0.05 0.53 ± 0.08 0.49 0.0017
Pentamidine 0.0034 ± 0.0004 0.55 ± 0.03 159 6.10 × 10−5
RF, Resistance factor; EC50 (resistant strain)/EC50 (WT). RF≤ 1 means no cross resistance with Pentamidine; RF significantly>1 shows cross resistance. All EC50 values are the average
and SEM of three independent determinations. Statistical significance was determined using Student’s unpaired t-test; P < 0.05 is considered significant. Molecular weight of bokkosin
= 632.75 g/mol.
TABLE 4 | EC50 of bokkosin on T. congolense IL3000 WT and T. congolense 6C3.
Sample T. congolense IL3000 WT T. congolense 6C3 (Diminazene resistant)
EC50 EC50 RF t-test
(µg/mL) (µM) (µg/mL) (µM)
Bokkosin 21.6 ± 2.0 34.8 ± 3.2 17.5 ± 0.4 28.4 ± 0.6 0.81 0.11
Diminazene 0.30 ± 0.07 1.6 ± 0.3 5.4 0.015
RF, Resistance factor; EC50 (resistant strain)/EC50 (WT). All EC50 values are the average and SEM of three independent determinations. Statistical significance was determined using
Student’s unpaired t-test; P < 0.05 is considered significant.
TABLE 5 | EC50 of bokkosin on L. mexicana cas9/T7 and L. mexicana cas9
1NT1.
Sample L. mexicana cas9/T7 L. mexicana cas91NT1
EC50 EC50 RF t-test
(µg/mL) (µM) (µg/mL) (µM)
Bokkosin 5.8 ± 1.5 9.1 ± 2.4 9.2 ± 0.9 14.5 ± 1.4 1.59 0.12
Tuberculin 0.44 ± 0.01 24.8 ± 0.2 56.6 <0.0001
Pentamidine 0.84 ± 0.13 0.91 ± 0.02 1.08 0.65
RF, Resistance factor; EC50 (resistant strain)/EC50 (WT). All EC50 values are the average and SEM of three independent determinations. Statistical significance was determined using
Student’s unpaired t-test; P < 0.05 is considered significant.
on the drug concentration. At 4× EC50 growth did not recover
over the period of the experiment, and growth arrest appears to
have been irreversible, although a definitive assessment would
require an even longer incubation time. This shows that bokkosin
is trypanocidal upon prolonged exposure and trypanostatic
on short exposure. Generally, for the translation into in vivo
activity, a short minimum exposure time for a drug is desirable
and may reduce potential toxic effects associated with keeping
compounds at peak circulation levels for longer. In this respect,
it is encouraging that the compound, even at concentrations ≤
EC50 and submicromolar, strongly impacted cell density within
the first 2 h. In addition, the practicalities of treating animal
trypanosomiasis, for instance, make it highly desirable that
a single administration be effective. Consequently, the strong
inhibitory effect of even the limited exposure time of T. b. brucei
to the test compound suggests that the compound is promising,
at least against this trypanosome species.
In vitro Cytotoxicity of Bokkosin on
Mammalian Cells
In order to determine whether the activity of bokkosin is
specifically antiprotozoal or the result of general toxicity, the
compound was tested on U937 human cells and RAW267.4
murine cells. Bokkosin showed low toxicity to these cell
lines, with EC50 values >200µM, thus displaying remarkable
selectivity against kinetoplastid parasites compared to the
mammalian cells, as shown in Table 6. Although this did not
result in high selectivity index (SI) values for T. congolense
and L. mexicana, the SI for both T. brucei strains were >200,
which should be considered encouraging for all T. brucei-group
species, which include the animal pathogens T. b. brucei, T.
evansi, T. b. rhodesiense, and T. equiperdum, as well as the
causative agents of HAT, T. b. gambiense and T. b. rhodesiense,
but not T. congolense or T. vivax (Giordani et al., 2016). However,
it could be surmised that the large bokkosin molecule may
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FIGURE 2 | Growth of T. brucei s427WT in drug free culture (control) or in the presence of 0.5×, 1×, 2× or 4× the EC50 concentration of bokkosin. Cell seeding
density was 2 × 105 cells/mL in HMI-9 with 10% (v/v) FBS, incubated at 37◦C and 5% CO2 (drug free) and counted at 0, 2, 6, 12, 18, 24, 30, 36, 42, and 48 h.
Growth curves show the effect of test compounds on trypanosome growth after a limited exposure of 2 h (A) or continuous exposure to the drug (B). Cell counts are
averages of three independent experiments, each counted in triplicate.
TABLE 6 | EC50 of bokkosin against two mammalian cell lines, and the Selectivity Indices for the three kinetoplastid species tested.
Sample U937 RAW 246.7 Selectivity Index (S.I) for wild-type
Mean of EC50 Mean of EC50 T. brucei T. congolense L. mexicana
(µg/mL) (µM) (µg/mL) (µM) U937 RAW U937 RAW U937 RAW
Bokkosin 170 ± 7 269 149 ± 5 230 246 215 7.8 6.8 29.5 25.8
SI, Selectivity Index; IC50 (mammalian cell)/EC50 (parasite). All EC50 values are the average and SEM of three independent determinations.
not be able to cross the blood brain barrier (BBB) and may
therefore only have effect in (early) haemolymphatic stage HAT.
A new HAT drug would be most valuable if active against
both the late, cerebral stage and the haemolymphatic one, but
it should be noted that a non-toxic treatment of early-stage
HAT would still be potentially valuable. Until very recently,
the recommended treatment for early stage gambiense HAT
has been pentamidine, since the 1940s, although fexinidazole
is now slightly favored for children older than 6 years because
of the oral route of administration; both drugs have similar
cure rates and levels of adverse effects (Lindner et al., 2020).
For early stage rhodesiense HAT the treatment has remained
suramin since 1920 (de Koning, 2020). Nor can it be assumed
a priori that bokkosin decidedly will not cross the BBB, as it
clearly enters the trypanosome readily enough and, considering
its size, this is unlikely to be via a species-specific nutrient
transporter as is the case for other trypanocides (Munday et al.,
2015). More important yet, bokkosin should now be tested
against the dyskinetoplastic trypanosome species T. evansi and T.
equiperdum, which are very closely related to T. brucei (Cuypers
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et al., 2017). These species are the etiological agents of the
veterinary conditions surra and dourine, respectively, and are not
(necessarily) transmitted by the tsetse fly and thus not limited to
sub-Saharan Africa; as such it avoids the potential complication
of co-infection with T. congolense that would be common in
AAT (Giordani et al., 2016).
CONCLUDING REMARKS
A new compound, bokkosin, was isolated from the traditional
medicinal plant C. portoricensis and found to be in a novel,
unique class. The compound showed promising activity against
T. brucei, but only moderate activity against T. congolense
and Leishmania species. The trypanocidal activity was almost
irreversible even after brief exposure at modest concentrations,
while toxicity to mammalian cell types was very low. Thus,
bokkosin is a completely new chemical entity, with potent, rapid
antitrypanosomal activity against T. b. brucei and low toxicity.
A logical next step would be the testing of bokkosin against
other brucei group trypanosomes such as T. equiperdum and T.
evansi, dyskinetoplastic trypanosomes causing diseases including
dourine in Asia, surra in camels in the Middle East, in water
buffaloes in southern Asia and horses and dogs in South America
(Aregawi et al., 2019).
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